<DOC>
	<DOCNO>NCT00924729</DOCNO>
	<brief_summary>This study conduct evaluate intraocular penetration Moxifloxacin 0.5 % ophthalmic solution ( Vigamox ) Besifloxacin 0.6 % ophthalmic suspension ( Besivance ) pre-operative topical administration subject undergo cataract surgery .</brief_summary>
	<brief_title>Study Ocular Penetration Topically Administered Fluoroquinolones</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Eye Injuries , Penetrating</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>7- ( 3-aminohexahydro-1H-azepin-1-yl ) -8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Subjects visually significant cataract plan cataract surgery . Subjects willing/able sign informed consent approve Institutional Review Board . Subjects known hypersensitivity , allergy , contraindication fluoroquinolone medication , form . Subjects sign ocular infection active inflammation study eye . Subjects corneal pathology , include epithelial defect , corneal scarring , severe dry eye syndrome . Subjects use disallow medication ( include antibiotic ) time period designate described protocol . Subjects active chronic/recurrent ocular systemic disease uncontrolled likely increase risk infection patient confound result study . Subjects pregnant ( suspect pregnant ) nursing/lactating . Subjects participate study investigational drug device within 30 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>